# 2025-21509: DEA Caps 2026 Drug Production: From Heroin to Sudafed Limits

2025-21509, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-11-28, effective DEA proposes 2026 aggregate production quotas and assessments of annual needs for 2026; public comments due on or before December 15, 2025. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21509
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21509
- Title: Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2026
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 54745
- Published: 2025-11-28
- Effective: DEA proposes 2026 aggregate production quotas and assessments of annual needs for 2026; public comments due on or before December 15, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Caps 2026 Drug Production: From Heroin to Sudafed Limits

## Summary

The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2026. This affects drug makers and anyone involved in producing or using these substances. They’re asking for public comments by December 15, 2025, before finalizing the rules, which could impact production and supply next year.

## Abstract

The Drug Enforcement Administration (DEA) proposes to establish the 2026 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

## Effects PRIA read

- Proposed cuts to several Schedule II opioids: cost, medium. DEA proposes reduced 2026 aggregate production quotas for multiple Schedule II opioids — specifically codeine (for sale), morphine (for sale), fentanyl, hydrocodone (for sale), hydromorphone, oxycodone (for sale), and oxymorphone (for sale) — as reductions from their 2025 established APQ values; DE…
- Higher remifentanil quota for 2026: benefit, low. DEA proposes a higher 2026 APQ for remifentanil than the 2025 established APQ to support increasing domestic medical use (used primarily intravenously during and after surgeries) and growing export requirements, based on rising domestic usage since 2020 and export increases from 2022–2024.
- Noroxymorphone quota increased for product development: benefit, low. DEA proposes an increased 2026 APQ for noroxymorphone (for sale) from the 2025 established APQ to accommodate a manufacturer's request to manufacture reference standards, identify unknown impurities, and conduct product development manufacturing activities.
- Stimulant quotas: some kept, lisdexamfetamine raised: benefit, medium. DEA observed a 6.74 percent increase in 2024 domestic use of Schedule II stimulants (amphetamine, methylphenidate, lisdexamfetamine) versus 2023. DEA proposes to set 2026 APQs for d-amphetamine (for sale), d,l-amphetamine, and methylphenidate at their 2025 adjusted APQ levels, and proposes to incre…
- Higher Schedule I quotas for research substances: benefit, low. DEA proposes higher 2026 APQs than 2025 for certain Schedule I substances — including 3,4-methylenedioxy-N-methylcathinone, 5-methoxy-N,N-dimethyltryptamine, psilocybin, and psilocyn — to support increased research and clinical trials studying potential treatments for conditions such as PTSD and de…
- AAN set for ephedrine, pseudoephedrine, phenylpropanolamine: mixed, medium. DEA proposes the 2026 assessment of annual needs (AAN) for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, and states the AAN includes imports of these chemicals (but excludes imports of controlled substances for use in industrial processes).
- All other Schedule I/II quotas proposed at zero: cost, low. DEA proposes that the APQ for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero for 2026.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-21509 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/28/2025-21509/proposed-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances-and-assessment-of)
- [2025-21509 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-28/pdf/2025-21509.pdf)

## Related
- [Previous: 2025-21508, Sunshine Act Meetings: Notice of Meeting Held With Less Than Seven Days Advance…](https://policyrisk.com/federal-register/2025-21508)
- [Next: 2025-21510, Privacy Act of 1974; System of Records](https://policyrisk.com/federal-register/2025-21510)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21509 (as of 2026-06-08).
